摘要
目的:探讨普伐他汀(pravastatin)对糖尿病大鼠肾脏氧化应激反应的影响及其机制。方法:将SD大鼠随机分为正常对照组(CN)、糖尿病对照组(DM)、普伐他汀治疗组(DM+P)、褪黑素治疗组(DM+M),每组7只。使用链脲佐菌素(STZ)诱导制备糖尿病大鼠模型。治疗组分别予普伐他汀和对照药物褪黑素(Mel)治疗,8周后检测大鼠血及肾组织中各项生化指标及各项抗氧化指标。结果:成功建立大鼠糖尿病模型。与DM组比较,Mel治疗可使24 h尿蛋白量显著降低(P<0.05),DM+P组尿蛋白排泄量降低更为明显(P<0.01);与DM组比较,DM+P组肾重/体质量比值有所下降(P<0.05)。与DM、DM+M相比,普伐他汀处理对糖尿病大鼠血浆MDA含量、红细胞SOD活性变化无明显影响,但可使全血谷胱甘肽过氧化物酶(GSH-Px)活性在8周时明显升高(P<0.01)。普伐他汀和Mel处理均可使糖尿病大鼠肾脏SOD活性、GSH-Px活性明显升高(P<0.05),普伐他汀还可使肾脏MDA含量显著下降(P<0.01)。结论:普伐他汀能明显改善糖尿病大鼠的肾功能,这可能与其抑制糖尿病大鼠肾脏氧化应激反应有关。
Objective:To investigate the effect of pravastatin on oxidative stress and renal function in the kidney of diabetic rats. Methods: SD rats were randomly divided into normal control group(CN), diabetic control group (DM), pravastatin treatment group (DM+P) and melatonin treatment group (DM+M). Pravastatin or melatonin was given to streptozocin-induced diabetic rat for 8 weeks, then the general state and renal function of rats were evaluated. The serum and renal intrinsic anti-oxidant enzyme(AOE) activities and lipid peroxide levels were also examined. Results: Diabetic rat model was successfully induced. Compared with DM control group, the urinary protein excretion was lower in DM+M group (P〈0.05) and DM+P group (P〈0.01). Pravastatin also decreased the renal weight/body weight ratio (P〈0.05). There was no significant difference in serum lipid peroxide levels and superoxide dismutase(SOD) activities between DM+P group, DM group and DM+M group, while glutathione peroxidase (GSH-Px) activities increased significantly in DM+ P group (P〈 0.01). Pravastatin and melatonin both increaseed the SOD and GSH-Px activities in renal cortex of diabetic rats (P〈0.05) ; pravastatin also reduced the renal lipid peroxide levels (P〈0.01). Conclusion: Pravastatin can improve renal function in diabetic rats, partly due to its inhibitory effect on oxidative stress in the kidneys of diabetic rats.
出处
《第二军医大学学报》
CAS
CSCD
北大核心
2005年第11期1266-1269,共4页
Academic Journal of Second Military Medical University
关键词
糖尿病
肾
普伐他汀
氧化应激
diabetes
kidney
pravastatin
oxidative stress